Vistin Pharma ASA (LTS:0RAM) Cash Payments for Loans

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RAM Vistin Pharma ASA LTS:0RAM
68 GF Score
Price kr19.15
GF Value kr23.59
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Cash Payments for Loans?

Cash Payments for Loans only applicable to companies reporting Cash Flow from Operations in direct method.

LTS:0RAM
68GF Score
Vistin Pharma ASA LTS:0RAM
Cash Payments for Loans is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr19.15 is trading 18.8% below its estimated GF Value™ of kr23.59. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for LTS:0RAM:

  • Cash Payments for Loans:
  • GF Value™: kr23.59 vs. price of kr19.15 (18.8% below fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
68GF Score

Get the complete analysis for LTS:0RAM

Cash Payments for Loans is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr19.15
Price
kr23.59
GF Value